Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Alpine Immune Sciences, Inc.

GSK vs. Alpine: A Decade of R&D Investment

__timestamp	Alpine Immune Sciences, Inc.	GSK plc
Wednesday, January 1, 2014	12199547	3450000000
Thursday, January 1, 2015	16054000	3560000000
Friday, January 1, 2016	23316000	3628000000
Sunday, January 1, 2017	10626000	4476000000
Monday, January 1, 2018	28970000	3893000000
Tuesday, January 1, 2019	35847000	4568000000
Wednesday, January 1, 2020	27185000	5098000000
Friday, January 1, 2021	58742000	5278000000
Saturday, January 1, 2022	70243000	5488000000
Sunday, January 1, 2023	80904000	6223000000

Unleashing the power of data

Innovation in the Pharmaceutical Industry: A Comparative Analysis

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, GSK plc and Alpine Immune Sciences, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, GSK's R&D expenses have consistently dwarfed those of Alpine, with GSK investing nearly 50 times more annually on average. In 2023, GSK's R&D spending reached its peak at approximately $6.2 billion, reflecting a 44% increase from 2014. Meanwhile, Alpine's R&D expenses, though significantly smaller, have shown a remarkable growth trajectory, increasing by over 560% during the same period. This stark contrast highlights the diverse strategies within the industry, where established giants and emerging innovators both play crucial roles in advancing medical science.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025